Skeletal Development and Regeneration Research: Jennifer J. Westendorf

Chromosomal Translocations and Cancer

Enlarge image

Chromosomal translocations

Close

Pax3-Maml3 expression (green) in C2C12 cells. DNA is stained blue and actin is red. Credit: Krista Bledsoe, Ph.D.

Dr. Westendorf's Skeletal Development and Regeneration Research Laboratory is studying chromosomal translocations and bone cancers, including primary and metastatic tumors.

The goal of Dr. Westendorf's research on chromosomal translocations and cancer is to discover and understand novel genes and mutations that contribute to bone cancers, sarcomas and leukemia.

Mayo Clinic collaborators: Haojie Huang, Ph.D.; Andre M. Oliveira, M.D., Ph.D.; Rajiv Kumar, Ph.D.; Shizhen (Jane) Zhu, M.D., Ph.D.

Related publications

• Berent TE, Dorschner JM, Craig TA, Drake MT, Westendorf JJ, Kumar R. Lung tumor cells inhibit bone mineralization and osteoblast activity. Biochemical and Biophysical Research Communications. 2019; doi:10.1016/j.bbrc.2019.09.045.
• Sterner RM, Kremer KN, Dudakovic A, Westendorf JJ, van Wijnen AJ, Hedin KE. Tissue-nonspecific alkaline phosphatase is required for MC3T3 osteoblast-mediated protection of acute myeloid leukemia cells from apoptosis. Journal of Immunology. 2018; doi:10.4049/jimmunol.1800174.
• Yang Y, Bai Y, He Y, Zhao Y, Chen J, Ma L, Pan Y, Hinten M, Zhang J, Karnes RJ, Kohli M, Westendorf JJ, Li B, Zhu R, Huang H, Xu W. PTEN loss promotes intratumoral androgen synthesis and tumor microenvironment remodeling via aberrant activation of RUNX2 in castration-resistant prostate cancer. Clinical Cancer Research. 2018; doi:10.1158/1078-0432.CCR-17-2006.
• Yan Y, An J, Yang Y, Wu D, Bai Y, Cao W, Ma L, Chen J, Yu Z, He Y, Jin X, Pan Y, Ma T, Wang S, Hou X, Weroha SJ, Karnes RJ, Zhang J, Westendorf JJ, Wang L, Chen Y, Xu W, Zhu R, Wang D, Huang H. Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in PTEN- or SPOP-mutated prostate cancer. EMBO Molecular Medicine. 2018; doi:10.15252/emmm.201708478.
• Sterner RM, Kremer KN, Al-Kali A, Patnaik MM, Gangat N, Litzow MR, Kaufmann SH, Westendorf JJ, van Wijnen AJ, Hedin KE. Histone deacetylase inhibitors reduce differentiating osteoblast-mediated protection of acute myeloid leukemia cells from cytarabine. Oncotarget. 2017; doi:10.18632/oncotarget.21809.
• Fang D, Gan H, Lee JH, Han J, Wang Z, Riester SM, Jin L, Chen J, Zhou H, Wang J, Zhang H, Yang N, Bradley EW, Ho TH, Rubin BP, Bridge JA, Thibodeau SN, Ordog T, Chen Y, van Wijnen AJ, Oliveira AM, Xu RM, Westendorf JJ, Zhang Z. The histone H3.3K36M mutation reprograms the epigenome of chondroblastomas. Science. 2016; doi:10.1126/science.aae0065.
• Wang X, Bledsoe KL, Graham RP, Asmann YW, Viswanatha DS, Lewis JE, Lewis JT, Chou MM, Yaszemski MJ, Jen J, Westendorf JJ, Oliveira AM. Recurrent PAX3-MAML3 fusion in biphenotypic sinonasal sarcoma. Nature Genetics. 2014; doi:10.1038/ng.2989.
• Westendorf JJ, Yamamoto CM, Lenny N, Downing JR, Selsted ME, Hiebert SW. The t(8; 21) fusion product, AML-1-ETO, associates with C/EBP-alpha, inhibits C/EBP-alpha-dependent transcription, and blocks granulocytic differentiation. Molecular and Cellular Biology. 1998; doi:10.1128/mcb.18.1.322.
• Lutterbach B, Westendorf JJ, Linggi B, Patten A, Moniwa M, Davie JR, Huynh KD, Bardwell VJ, Lavinsky RM, Rosenfeld MG, Glass C, Seto E, Hiebert SW. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors. Molecular and Cellular Biology. 1998; doi:10.1128/mcb.18.12.7176.